6 The use of anti-progesterones as a medical IUD

Lynnette K. Nieman, Donald (Lynn) Loriaux

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Mifepristone holds promise as a safe and effective anti-progesterone. Wide-spread use of mifepristone to regularize cycles or prevent pregnancy, however, cannot be recommended at this time. The drug is promising for these uses but the dose and timing of administration required to achieve optimum effect are unknown. Menses are consistently induced in the mid to late luteal phase at a wide range of doses. Further work needs to be done to examine the luteolytic properties of the drug when given at this time. Knowledge about the serum concentration of the parent compound and its less active metabolites after oral administration may help to explain variable biological effects. The effects of other modes of administration, such as transdermal or transvaginal application which avoid a first-pass effect by the liver, should also be explored. Practical issues of the timing of administration need to be resolved. The drug is not effective when given in the absence of luteal phase levels of progesterone. Thus, verification of luteal phase status before the administration of the drug would be ideal. Basal body temperature monitoring may be one way to do this. There is no other convenient way to determine serum levels of progesterone that would be feasible on a large-scale outpatient basis. Since mifepristone does not regulate the timing of ovulation, the optimal time of administration may vary from cycle to cycle. This presumes a high degree of willingness on the part of the woman to observe her cycles and participate in decisions regarding the timing of the drug. Mifepristone, the first clinically available anti-progesterone, represents a significant advance in fertility control. Further work is necessary to define the optimal dose and schedule of administration in the luteal phase and to explore the contraceptive efficacy in women at risk for pregnancy.

Original languageEnglish (US)
Pages (from-to)609-616
Number of pages8
JournalBailliere's Clinical Obstetrics and Gynaecology
Volume2
Issue number3
DOIs
StatePublished - 1988
Externally publishedYes

Fingerprint

Mifepristone
Luteal Phase
Progesterone
Pharmaceutical Preparations
Pregnancy
Menstruation
Contraceptive Agents
Ovulation
Body Temperature
Serum
Contraception
Oral Administration
Appointments and Schedules
Outpatients
Liver

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

6 The use of anti-progesterones as a medical IUD. / Nieman, Lynnette K.; Loriaux, Donald (Lynn).

In: Bailliere's Clinical Obstetrics and Gynaecology, Vol. 2, No. 3, 1988, p. 609-616.

Research output: Contribution to journalArticle

@article{756e955f2d8041d49bf304f9b4bd9e1e,
title = "6 The use of anti-progesterones as a medical IUD",
abstract = "Mifepristone holds promise as a safe and effective anti-progesterone. Wide-spread use of mifepristone to regularize cycles or prevent pregnancy, however, cannot be recommended at this time. The drug is promising for these uses but the dose and timing of administration required to achieve optimum effect are unknown. Menses are consistently induced in the mid to late luteal phase at a wide range of doses. Further work needs to be done to examine the luteolytic properties of the drug when given at this time. Knowledge about the serum concentration of the parent compound and its less active metabolites after oral administration may help to explain variable biological effects. The effects of other modes of administration, such as transdermal or transvaginal application which avoid a first-pass effect by the liver, should also be explored. Practical issues of the timing of administration need to be resolved. The drug is not effective when given in the absence of luteal phase levels of progesterone. Thus, verification of luteal phase status before the administration of the drug would be ideal. Basal body temperature monitoring may be one way to do this. There is no other convenient way to determine serum levels of progesterone that would be feasible on a large-scale outpatient basis. Since mifepristone does not regulate the timing of ovulation, the optimal time of administration may vary from cycle to cycle. This presumes a high degree of willingness on the part of the woman to observe her cycles and participate in decisions regarding the timing of the drug. Mifepristone, the first clinically available anti-progesterone, represents a significant advance in fertility control. Further work is necessary to define the optimal dose and schedule of administration in the luteal phase and to explore the contraceptive efficacy in women at risk for pregnancy.",
author = "Nieman, {Lynnette K.} and Loriaux, {Donald (Lynn)}",
year = "1988",
doi = "10.1016/S0950-3552(88)80047-6",
language = "English (US)",
volume = "2",
pages = "609--616",
journal = "Bailliere's Clinical Obstetrics and Gynaecology",
issn = "0950-3552",
publisher = "Bailliere Tindall Ltd",
number = "3",

}

TY - JOUR

T1 - 6 The use of anti-progesterones as a medical IUD

AU - Nieman, Lynnette K.

AU - Loriaux, Donald (Lynn)

PY - 1988

Y1 - 1988

N2 - Mifepristone holds promise as a safe and effective anti-progesterone. Wide-spread use of mifepristone to regularize cycles or prevent pregnancy, however, cannot be recommended at this time. The drug is promising for these uses but the dose and timing of administration required to achieve optimum effect are unknown. Menses are consistently induced in the mid to late luteal phase at a wide range of doses. Further work needs to be done to examine the luteolytic properties of the drug when given at this time. Knowledge about the serum concentration of the parent compound and its less active metabolites after oral administration may help to explain variable biological effects. The effects of other modes of administration, such as transdermal or transvaginal application which avoid a first-pass effect by the liver, should also be explored. Practical issues of the timing of administration need to be resolved. The drug is not effective when given in the absence of luteal phase levels of progesterone. Thus, verification of luteal phase status before the administration of the drug would be ideal. Basal body temperature monitoring may be one way to do this. There is no other convenient way to determine serum levels of progesterone that would be feasible on a large-scale outpatient basis. Since mifepristone does not regulate the timing of ovulation, the optimal time of administration may vary from cycle to cycle. This presumes a high degree of willingness on the part of the woman to observe her cycles and participate in decisions regarding the timing of the drug. Mifepristone, the first clinically available anti-progesterone, represents a significant advance in fertility control. Further work is necessary to define the optimal dose and schedule of administration in the luteal phase and to explore the contraceptive efficacy in women at risk for pregnancy.

AB - Mifepristone holds promise as a safe and effective anti-progesterone. Wide-spread use of mifepristone to regularize cycles or prevent pregnancy, however, cannot be recommended at this time. The drug is promising for these uses but the dose and timing of administration required to achieve optimum effect are unknown. Menses are consistently induced in the mid to late luteal phase at a wide range of doses. Further work needs to be done to examine the luteolytic properties of the drug when given at this time. Knowledge about the serum concentration of the parent compound and its less active metabolites after oral administration may help to explain variable biological effects. The effects of other modes of administration, such as transdermal or transvaginal application which avoid a first-pass effect by the liver, should also be explored. Practical issues of the timing of administration need to be resolved. The drug is not effective when given in the absence of luteal phase levels of progesterone. Thus, verification of luteal phase status before the administration of the drug would be ideal. Basal body temperature monitoring may be one way to do this. There is no other convenient way to determine serum levels of progesterone that would be feasible on a large-scale outpatient basis. Since mifepristone does not regulate the timing of ovulation, the optimal time of administration may vary from cycle to cycle. This presumes a high degree of willingness on the part of the woman to observe her cycles and participate in decisions regarding the timing of the drug. Mifepristone, the first clinically available anti-progesterone, represents a significant advance in fertility control. Further work is necessary to define the optimal dose and schedule of administration in the luteal phase and to explore the contraceptive efficacy in women at risk for pregnancy.

UR - http://www.scopus.com/inward/record.url?scp=0024262735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024262735&partnerID=8YFLogxK

U2 - 10.1016/S0950-3552(88)80047-6

DO - 10.1016/S0950-3552(88)80047-6

M3 - Article

C2 - 3233821

AN - SCOPUS:0024262735

VL - 2

SP - 609

EP - 616

JO - Bailliere's Clinical Obstetrics and Gynaecology

JF - Bailliere's Clinical Obstetrics and Gynaecology

SN - 0950-3552

IS - 3

ER -